Shanghai - Delayed Quote CNY

Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS)

237.10 +0.16 (+0.07%)
At close: May 17 at 3:00 PM GMT+8
Loading Chart for 600436.SS
DELL
  • Previous Close 236.94
  • Open 236.12
  • Bid 237.10 x --
  • Ask 237.11 x --
  • Day's Range 234.50 - 237.60
  • 52 Week Range 180.69 - 315.98
  • Volume 1,620,021
  • Avg. Volume 1,852,796
  • Market Cap (intraday) 143.046B
  • Beta (5Y Monthly) 0.78
  • PE Ratio (TTM) 47.61
  • EPS (TTM) 4.98
  • Earnings Date --
  • Forward Dividend & Yield 1.25 (0.53%)
  • Ex-Dividend Date Jul 12, 2023
  • 1y Target Est 277.57

Zhangzhou Pientzehuang Pharmaceutical., Ltd engages in the manufacture and sale of Chinese medicines under the Pien Tze Huang brand in China and internationally. Its products include Chinese herbal decoction pieces, health foods, beverages, medical equipment, tonics, Chinese herbal medicine slices, cosmetics, and daily chemical products. The company was founded in 1956 and is based in Zhangzhou, China. Zhangzhou Pientzehuang Pharmaceutical., Ltd is a subsidiary of Zhangzhou Jiulongjiang Group Co., Ltd.

www.zzpzh.com.cn

2,789

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 600436.SS

Performance Overview: 600436.SS

Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

600436.SS
2.02%
SSE Composite Index
6.02%

1-Year Return

600436.SS
22.08%
SSE Composite Index
4.16%

3-Year Return

600436.SS
35.88%
SSE Composite Index
9.64%

5-Year Return

600436.SS
118.15%
SSE Composite Index
6.71%

Compare To: 600436.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 600436.SS

Valuation Measures

Annual
As of 5/17/2024
  • Market Cap

    143.05B

  • Enterprise Value

    141.94B

  • Trailing P/E

    47.61

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    13.49

  • Price/Book (mrq)

    9.98

  • Enterprise Value/Revenue

    13.39

  • Enterprise Value/EBITDA

    39.04

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    28.32%

  • Return on Assets (ttm)

    12.98%

  • Return on Equity (ttm)

    22.17%

  • Revenue (ttm)

    10.6B

  • Net Income Avi to Common (ttm)

    3B

  • Diluted EPS (ttm)

    4.98

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.37B

  • Total Debt/Equity (mrq)

    8.54%

  • Levered Free Cash Flow (ttm)

    -890.19M

Research Analysis: 600436.SS

Company Insights: 600436.SS

Research Reports: 600436.SS

People Also Watch